Patients with heart damage from major non-cardiac surgery (MINS) had a lower risk of dying if they took dabigatran twice a day, depending on results of a study published in the medical journal The Lancet.
Researchers McMaster University, Hamilton, Ontario, Canada conducted their study with 1,754 patients from 19 different countries. 51% of them were men, on average 70 years old.
A previous study found that patients with heart damage after major non-cardiac surgery (MINS) were 2% less likely to die if they took dabigatran twice a day. This observation was identical for the heart attack, the’Stroke, development of blood clots or amputation due to heart disease.
This new 16-month study has shown that patients treated with dabigatran had 28% less risk of serious side effects.
Dabigatran effective in reducing the risk of recurrence
Compared to volunteers who received a placebo, patients treated with dabigatran were 20% less likely to die from cardiovascular causes, to have heart attack (20%), 30% lower risk of having an amputation and 53% less likely to develop a venous blood clot. The results show up to 80% for theStroke non-hemorrhagic.
“For the first time, our team has shown that dabigatran reduces the risk of major cardiovascular complications in patients with MINS,” explained PJ Devereaux, lead author of the study and professor in the Department of Health Research at the McMaster University, Hamilton, Ontario, Canada.
However, an increased risk of bleeding was observed in the group of participants treated with the anticoagulant. “In patients with NIMS, the dabigatran at 110 mg twice a day reduces the risk of major vascular complications, without a significant increase in major bleeding, ”the team of researchers concludes.
Read also :
After a heart attack, how about tai chi?
An anti-inflammatory drug would reduce the risk of heart attack
Anger and heavy sport could break your heart
